References
Adler I. Primary malignant growths of the lungs and bronchi: a pathological and clinical study. New York: Longmans, Green, and Co; 1912.
Cancer Facts & Figures 2021, American Cancer Society (ACS), Atlanta, Georgia, 2021.
Sung H, Ferlay J, Siegel R. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 186 countries // Ca: Cancer J Cli 2021; 71: 209-249. doi:10.3322/caac.21660
Howlander N, Forjaz G, Mooradian M. et al. The effect of advances in lung-cancer treatment on population mortality // NEJM 2020; 383: 640-649. doi:10.1056/NEJMoa1916623
Ganti A, Klein A, Cotarla I. et al. Update on incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US // JAMA Oncol. Published online October 21, 2021. doi:10.1001/jamaoncol.2021.4932.
What Are the Risk Factors for Lung Cancer?, CDC, 2021
Peres J. No clear link between passive smoking and lung cancer // Journal of the National Cancer Institute 2013; 105, 24: 1844–1846, doi:10.1093/jnci/djt365.
Clarke E, Thompson K, Weaver S. et al. Snus: a compelling harm reduction alternative to cigarettes // Harm Reduction Journal 2019; 16: 62. doi:10.1186/s12954-019-0335-1
Lung cancer incidence in 2018.
https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/lung-cancer/
.
Gupta S, Gupta R, Sinha D, and Mehrotra R. Relationship between type of smokeless tobacco and risk of cancer: a systematic review // Indian J Med Res 2018; 148, July: 56-76. doi:10.4103/ijmr.IJMR_2023_17
Pelosof L, Ahn C, Gao A. et al. Proportion of never-smoker non-small cell lung cancer patients at three diverse institutions // J Natl Cancer Inst 2017; 109 (7): djw295. doi:10.1093/jnci/djw295.
More countries act against exposure to radon and associated cancer risks // WHO news. Published 4 February 2021. https://www.who.int/news/item/04-02-2021-more-countries-act-against-exposure-to-radon-and-associated-cancer-risks.
Berg C. Global variability in lung cancer deaths attributable to air pollution // 2021 World Conference in Lung Cancer, abstract PL02.07.
Kanwal M, Ding X-J, Cao Y. Familial risk for lung cancer (review) // Oncology Letters 2017; 13: 535-542. doi:10.3892/ol.2016.5518.
Durham A, Adcock I. The relationship between COPD and lung cancer // Lung Cancer 2015; 90: 121-127. doi:10.1016/j.lungcan.2015.08.017.
Shieh S, Probst J, Sung F. et al. Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes // BMC Cancer 2012; 12: 174. doi:10.1186/1471-2407-12-174.
Read W, Tierney R, Page N. et al. Differential prognostic impact of comorbidity // J Clin Oncol 2004; 22: 3099-3103.
Morgensztern D, Ng S, Gao F. et al. Trends in stage distribution for patients with non-small cell lung cancer: A National Cancer Database survey // J Thorac Oncol 2010; 5: 29-33.
National Cancer Institute: Cancer Stat Facts: Lung and bronchus cancer //
https://seer.cancer.gov/statfacts/html/lungb.html
.
Gazzoni F, Severo L, Marchioni E. et al. Fungal diseases mimicking primary lung cancer: radiologic-pathologic correlation // Mycoses 2014; 57 (4): 197-208. doi:10.1111/myc.12150.
White C, Salis A, Meyer C. Missed lung cancer on chest radiography and computed tomography: imaging and medicolegal issue // J Thorac Imaging 1999; 14: 63–68.
Del Ciello A, Franchi P, Contegiacomo A. et al. Missed lung cancer: when, where, and why? // Diagn Interv Radiol 2017; 23: 118–126. doi:10.5152/dir.2016.16187.
Screening for lung cancer. US Preventive Services Task Force // JAMA 2021; 325(10): 962-970. doi:10.1001/jama.2021.1117
Copeland A, Criswell A, Ciupek A. and King J. Effectiveness of lung cancer screening implementation in the community setting in the United States // J Oncol Pract 2019; 15: e607-e615. doi:10.1200/JOP.18.00788.
Skoulidis F, Heymach J. Co-occurring genomic alterations in non-small cell lung cancer biology and treatment // Nat Rev Cancer 2019; 19 (9): 495-509. doi:10.1038/s41568-019-0179-8.
Non-small cell lung cancer. NCCN Clinical Practice Guidelines in Oncology. 2021
Freitas C, Sousa C, Machado F. et al. The role of liquid biopsy in early diagnosis of lung cancer // Front. Oncol 2021; 11: 634316. doi:10.3389/fonc.2021.634316.
Sherwood J, Dearden S, Ratcliffe M, and Walker J. Mutation status concordance between primary lesions and metastatic sites of advanced non-small cell lung cancer and the impact of mutation testing methodologies: a literature review // Journal of Experimental & Clinical Cancer Research 2015; 34:92.
Lee C, Soon Y, Tan C. et al. Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis // PLoS ONE 2019; 14(6): e0218414. https://doi.org/10.1371/journal.pone.0218414
Kerr K, Bibeau F, Thunnissen E. et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe // Lung cancer 2021; 154: 161-175. doi:10.1016/j.lungcan.2021.02.026
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up. Updated version published 15 September 2020 by the ESMO Guidelines Committee.
Scagliotti G, Parikh P, von Pawel, J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer // J. Clin. Oncol 2008; 26, 3543–3551.
Langer C, Gadgeel S, Borghaei H. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous, non-small-cell lung cancer: a randomised, phase cohort of the open-label KEYNOTE-021 study // Lancet Oncol 2016; 17: 1497–1508. doi:10.1016/S1470-2045(16)30498-3.
Sezer A, Kilickap S, Gumus M. et al. Cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of at least 50%: a multicenter, open-label, global, phase 3, randomized, controlled trial // Lancet 2021; 397 (10274): 592-604. doi:10.1016/S0140-6736(21)00228-2.
Rodriguez-Abreu D, Powell S, Hochmair M. et al. Final analysis of KEYNOTE-189: pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC) // J Clin Oncol 2020; 38: 15 (suppl). 2020 ASCO Annual Meeting abstract 9582.
Socinski M, Nishio M, Jotte R. et al. IMPower150 final overall survival analysis for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC // J Thoracic Oncology 2021; 16 (11): 1909-1924. doi:10.1016/j.jtho.2021.07.009.
Herbst R, Garon E, Kim D-W. et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study // J Clin Oncol, 2020; 38: 1580-1590. doi:10.1200/JCO.19.02446.
Al Achkar M, Marchand L, Thompson M. et al. Unmet needs and opportunities for improving care for patients with advanced lung cancer on targeted therapies: a qualitative study // BMJ Open 2020; 10: e032639. doi:10.1136/bmjopen-2019-032639.
Wang F, Wang S, Zhou Q. The resistance mechanisms of lung cancer immunotherapy // Front. Oncol 2020; 10: 568059. doi:10.3389/fonc.2020.568059.
FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC. FDA. May 28, 2021.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc
.
Ali A, Goffin J, Arnold A, and Ellis P. Survival of patients with non-small cell lung cancer after a diagnosis of brain metastases // Curr Oncol 2013; 20: e300-306. doi:10.3747/co.20.1481.
FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. FDA. May 21, 2021.
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer
.
Ramalingam S, Zhou C, Kim T, et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion+ metastatic NSCLC: additional results from platinum-pretreated patients and EXCLAIM cohort of phase 1/2 study // J Clin Oncol 2021;39 (suppl 15): 9014.
FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. FDA. September 16.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20
.
Sacher A, Le X, Cornelissen R, et al. Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 exon 20 mutant non-small cell lung cancer. Presented at: ESMO TAT Virtual Congress; March 1-2, 2021.
Enhertu granted breakthrough therapy designation in the US for HER2-mutant metastatic non-small cell lung cancer. News release. AstraZeneca. May 18, 2020.
https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-mutant-metastatic-non-small-cell-lung-cancer.html
.
Skoulidis F, Li B, Dy G, et al. Sotorasib for lung cancers with KRAS p.G12C mutation // N Engl J Med 2021; 384: 2371-2381. doi:10.1056/NEJMoa2103695.
Riely G, Ou S, Rybkin I, et al. KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation // J Thorac Oncol 2021;16 (suppl 4): S748. doi:10.1016/S1556-0864(21)01941-9.
FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer. FDA. February 3, 2021.
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer
.
FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer. FDA. May 6, 2020.
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer
.
Horn L, Wang Z, Wu G. et al. Ensartinib vs crizotinib for patients with anaplasticlymphoma kinase-positive non-small cell lung cancer. A randomized clinical trial // JAMA Oncol 2021; 7(11):1617-1625. doi:10.1001/jamaoncol.2021.3523.
Garcia, S., Bisen, A., Yan, J., Xie, X.-J., Ramalingam, S., Schiller, J. H., Johnson, D. H., & Gerber, D. E. (2017). Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity. Journal of Thoracic Oncology, 12(10), 1489–1495.
https://doi.org/10.1016/j.jtho.2017.07.020
Created with Sketch.